Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain favor with the European regulators for ...
April 24, 2026 10:49 AM EDTUpdated 11 hours ago PharmaFDA+ Novartis pulls Pluvicto prostate cancer label expansion filing in the EU Anna Brown News Reporter Novartis has withdrawn its EU application for Pluvicto’s expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that